A Phase I Study to Determine the Pharmacokinetic Profile, Safety and Tolerability of a Single Dose (50IU/kg) of KW-3357 in Subjects With Congenital Antithrombin Deficiency.
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2011
At a glance
- Drugs Antithrombin gamma (Primary)
- Indications Thrombosis
- Focus Pharmacokinetics
- 01 Apr 2011 Status changed from active, no longer recruiting to completed.
- 14 Oct 2010 Planned end date changed from 1 Oct 2010 to 1 Jul 2011 as reported by ClinicalTrials.gov.
- 14 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.